Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 3057 | Ordered by Date (descending)
1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Engrail Therapeutics–abrdn: investment, 202403 financing round Series B totalling $157m incl co-investor funds managed by abrdn Inc 2024-03-19
Engrail Therapeutics–F-Prime: investment, 202403 financing round Series B totalling $157m incl new + co-lead investor F-Prime Capital 2024-03-19
Engrail Therapeutics–SEVERAL: investment, 202403 financing round Series B $157m led by F-Prime + Forbion + Norwest 2024-03-19
Amolyt Pharma–AstraZeneca: investment, 202403– acquisition $800m upfront cash + $250m milestones 2024-03-14
Nuclera–Zyme Communications: public relations, 202403 service existent by Zyme 2024-03-14
Ricoh–ERS Genomics: CRISPR technology, 202001– license non-excl in US + Japan to Ricoh Company 2024-03-13
HiDocTechnologies–Mahana Therapeutics: investment, 202403 acquisition €na of Cara Care by Mahana Therapeutics 2024-03-12
Boehringer–Sosei: GPR52 agonists, 202403– collab drug discovery + excl ww license option €25m upfront + €730m milestones plus tiered royalties 2024-03-11
Inpart–Norstella: business services, 202409– collab integrating Evaluate data into Deal CRM of Inpart 2024-02-29
Neobe Therapeutics–SEVERAL: Investment, 202402 financing round $2.34m led by Pioneer Group incl grant from Innovate UK 2024-02-29
Cresset–Enamine: virtual drug screening, 202402– collab ww applying Ignite virtual screening technology to Enamine REAL Space library 2024-02-21
GlycanAge–SEVERAL: investment, 202402 seed financing round €3.9m led by LauncHub Ventures + Kadmos Capital 2024-02-19
MIP Discovery–Calculus Capital: investment, 202402 financing round Series A totalling £7m incl exsiting + co- investor Calculus Capital 2024-02-19
MIP Discovery–Mercia: investment, 202402 financing round Series A totalling £7m incl lead investor Mercia Ventures 2024-02-19
MIP Discovery–OTHER: investment, 202402 financing round Series A totalling £7m incl angel investors 2024-02-19
MIP Discovery–SEVERAL: investment, 202402 financing round Series A £7m led by Mercia Ventures 2024-02-19
Earlybird–SEVERAL: investment, 202402 final closing of new Earlybird Health Fund at €173m 2024-02-14
Earlybird–United Kingdom (govt): investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor British Patient Capital 2024-02-14
Newcells Biotech–Mercia: investment, 202402 financing round totalling £2.35m incl existing investor Mercia Ventures 2024-02-14
Newcells Biotech–Northstar Ventures: investment, 202402 financing round totalling £2.35m incl existing investor Northstar Ventures 2024-02-14
Newcells Biotech–SEVERAL: investment, 202402 financing round £2.35m from existing investors Mercia Ventures + Northstar Ventures 2024-02-14
Amply Discovery–SEVERAL: investment, 2024Q2 seed financing round £1.4m PLANNED NOT YET REALISED 2/24 2024-02-12
Amply Discovery–United Kingdom (govt): grant, 202402c grant £835k from Innovate UK + Innosuisse to develop RNAi therapy for AML 2024-02-12
Amply Discovery–United Kingdom (govt): grant, 202402c Innovate UK grant £602k to develop inhaled antimicrobial therapies for MDR lung infections 2024-02-12
BugBiome–Cambridge Angels: investment, 202402 pre-seed financing round totalling £310k incl investor Cambridge Angels 2024-02-12
BugBiome–Discovery Park: investment, 202402 pre-seed financing round totalling £310k incl investor Discovery Park Ventures 2024-02-12
BugBiome–SEVERAL: investment, 202402 pre-seed financing round £310k from Cambridge Angels + Discovery Park Ventures 2024-02-12
BugBiome–United Kingdom (govt): grant, 202402– Innovate UK grant £330k to identify methods to control aphids in crop protection 2024-02-12
Zetta Genomics–Apex Ventures: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Apex Ventures 2024-02-08
Zetta Genomics–Nina Capital: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Nina Capital 2024-02-08
Zetta Genomics–SEVERAL: investment, 202402 2nd seed financing round expansion by £1.8m to total of £3.7m 2024-02-08
Zetta Genomics–Univ Cambridge: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Univ Cambridge 2024-02-08
Zetta Genomics–Werfen: investment, 202402 2nd seed financing round expansion totalling £1.8m incl new investor We Venture Capital 2024-02-08
Sablebio–Episode 1 Ventures: investment, 202402 pre-seed financing round totalling £1.5m incl lead investor Episode 1 Ventures 2024-02-06
Sablebio–PERSON: investment, 202402 pre-seed financing round totalling £1.5m incl co-investor Siddhant Jayakumar 2024-02-06
Sablebio–Seedcamp: investment, 202402 pre-seed financing round totalling £1.5m incl co-investor Seedcamp 2024-02-06
Sablebio–SEVERAL: investment, 202402 pre-seed financing round £1.5m led by Episode 1 Ventures 2024-02-06
Silence Therapeutics–5AM Ventures: investment, 202402 private placement totalling $120m incl investor 5AM Ventures 2024-02-05
Silence Therapeutics–Column Group: investment, 202402 private placement totalling $120m incl investor TCGX 2024-02-05
Silence Therapeutics–Frazier: investment, 202402 private placement totalling $120m incl investor Fazier Life Sciences 2024-02-05
Silence Therapeutics–Logos Capital: investment, 202402 private placement totalling $120m incl investor Logos Capital 2024-02-05
Silence Therapeutics–Nextech: investment, 202402 private placement totalling $120m incl investor Nextech Invest Ltd 2024-02-05
Silence Therapeutics–Redmile Group: investment, 202402 private placement totalling $120m incl investor Redmile Group 2024-02-05
Silence Therapeutics–SEVERAL: investment, 202402 private placement $120m mit 5.7m ADSs at $12/ADS 2024-02-05
Silence Therapeutics–Vivo Capital: investment, 202402 private placement totalling $120m incl investor Vivo Capital 2024-02-05
Enterprise Therapeutics–SEVERAL: investment, 202401 financing round Series B follow-on £26m led by Panakès Partners 2024-01-30
TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces 2024-01-30
Chemspeed–Bruker: investment, 202401– acquisition €na of Chemspeed Technology AG by Bruker 2024-01-25
Melio Health–Inizio: public relations, 202401 service existent to IMU Biosciences by Medistrava Consulting 2024-01-24
Melio Health–LifeX Ventures: investment, 202401 financing round Series A totalling £11.5m of IMU Biosciences incl co-investor LifeX Ventures 2024-01-24
Melio Health–Molten Ventures: investment, 202401 financing round Series A totalling £11.5m of IMU Biosciences incl lead investor Molten Ventures 2024-01-24
Melio Health–OTHER: investment, 202401 financing round Series A totalling £11.5m of IMU Biosciences incl individuals as co-investors 2024-01-24
Melio Health–SEVERAL: investment, 202401 financing round Series A £11.5m led by Molten Ventures 2024-01-24
Sano Genetics–Episode 1 Ventures: investment, 202401 financing round totalling $11.4m incl existing + co-investor Episode 1 2024-01-22
Sano Genetics–MMC Ventures: investment, 202401 financing round totalling $11.4m incl existing + co-investor MMC Ventures 2024-01-22
Sano Genetics–Plural: investment, 202401 financing round totalling $11.4m incl lead investor Plural 2024-01-22
Sano Genetics–Seedcamp: investment, 202401 financing round totalling $11.4m incl existing + co-investor Seedcamp 2024-01-22
Sano Genetics–SEVERAL: investment, 202401 financing round $11.4m led by Plural 2024-01-22
SyntheticGestalt–Enamine: AI-based drug discovery, 202401– collab adding REAL database to AI-based drug discovery service of SyntheticGestalt 2024-01-11
Aiolos Bio–GSK: investment, 202401– acquisition $1b upfront + $400m milestones 2024-01-09
Mesenbio–DSW Capital: investment, 202401 seed financing round totalling £1.4m incl co-lead investor DSW Ventures / Seed EIS Fund (with BBI) 2024-01-09
Mesenbio–NG Bio: investment, 202401 seed financing round totalling £1.4m incl co-lead investor NG Bio 2024-01-09
Mesenbio–SEVERAL: investment, 202401 seed financing round £1.4m co-led by DSW Ventures (with BBI) + NG Bio 2024-01-09
Mesenbio–United Kingdom (govt): grant, 202401 grant funding from Innovate UK 2024-01-09
Apollo Therapeutics–SEVERAL: investment, 202401 financing round Series C 2nd closing $33.5m bringing total Series C to $260m 2024-01-02
AstraZeneca–Allorion Therapeutics: EGFR inhibitor, 202401– excl option + ww license $40m upfront/near + >$500m milestones + royalties EGFR L858R AI 2024-01-02
LumiraDx–Roche: investment, 202312– acquisition $295m + $55m milestones of parts of LumiraDx Group related to innovative PoC technology 2023-12-29
Gracell Biotechnologies–AstraZeneca: investment, 202312– acquisition $1b upfront cash + $200m milestone-based CVRs 2023-12-26
Karuna–BMS: investment, 202312– acqusition $14b ($12.7b net of cash acquired) for $330/share common stock ANNOUNCED 2023-12-22
GSK–Hansoh Pharmaceutical: antibody-drug conjugates, 202312– license ww excl Greater China to HS-20093 $185m upfront + $1.525b milestones + royalties 2023-12-20
Metrion Biosciences–SEVERAL: investment, 202312 equity financing round £3.7m with lead investor Maven Capital Partners 2023-12-20
Icosavax–AstraZeneca: investment, 202312– tender offer $800m cash + $300m non-tradable CVRs by AstraZeneca 2023-12-12
Cerevel–AbbVie: investment, 202312– acquisition $8.7b in cash at $45/share of Cerevel Therapeutics by AbbVie 2023-12-06
Exscientia–Open Philanthropy: grant, 202312– grant $2.3m for research in host interferon response as therapeutic approach for pandemic influenza 2023-12-05
Odyssey Therapeutics–SEVERAL: investment, 202312 financing round Series C $101m led by Ascenta Capital 2023-12-05
Odyssey Therapeutics–SR One: investment, 202312 financing round Series C totalling $101m incl existing + co-investor SR One 2023-12-05
Freeline Therapeutics–Syncona: credit, 202311–202411 secured convertible loan note up to $15m with 12% interest + conversion price of $6.5/ADS 2023-11-22
Freeline Therapeutics–Syncona: investment, 202311– acquisition all remaining shares $6.5/ADS in going-private valuing entire issued capital at $28.3m 2023-11-22
Quotient Therapeutics–Flagship Pioneering: investment, 202311 Quotient Tx unveiled with initial $50m commitment from Flagship Pioneering 2023-11-21
AstraZeneca–Accenture: clinical research software, 202311– collab to accelerate + expand adoption of Evinova digital products globally 2023-11-20
AstraZeneca–Amazon: clinical research software, 202311– collab with AWS to accelerate + expand adoption of Evinova digital products globally 2023-11-20
Fortrea–AstraZeneca: clinical research software, 202311– strategic collab Fortrea offering Evinova digital health solutions to customers 2023-11-20
Parexel–AstraZeneca: clinical research software, 202311– strategic collab Parexel offering Evinova digital health solutions to customers 2023-11-20
T-Therapeutics–SEVERAL: investment, 202311 financing round Series A £48m 2023-11-15
Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise 2023-11-14
Novartis–GenScript: CAR-T cell therapies, 202311– license excl ww $100m upfront + $1.01b milestones + royalties for DLL CAR-Ts Legend Biotech 2023-11-13
ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital 2023-11-13
ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF 2023-11-13
ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation 2023-11-13
ViaNautis Bio–Meltwind: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Meltwind 2023-11-13
ViaNautis Bio–o2h: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor O2H 2023-11-13
ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital 2023-11-13
ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures 2023-11-13
ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures 2023-11-13
AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004 2023-11-09
Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV 2023-11-02
MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets 2023-10-30
Aiolos Bio–Atlas Venture: investment, 202310 financing round Series A totalling $245m incl co-lead investor Atlas Venture 2023-10-25
Aiolos Bio–Bain Capital: investment, 202310 financing round Series A totalling $245m incl co-lead investor Bain Capital Life Sciences 2023-10-25
Aiolos Bio–Forbion: investment, 202310 financing round Series A totalling $245m incl co-lead investor Forbion 2023-10-25
1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top